Article: Stem Cell Innovations Advancing Drug Discovery With PluriCells.

Staff Writer

At a time when the issue of embryonic stem cell research is making headlines again in the wake of a Senate bill calling for federal funding followed by the anticipation of an almost-certain presidential veto, a Houston-based cell biology company quietly is advancing its research with a slightly less controversial stem cell source.

Founded early last year, Stem Cell Innovations Inc. (SCI) was formed by the merger of three companies - Amphioxus Cell Technologies Inc., which focused on in vivo toxicology, along with Plurion Inc., which had intellectual property relating to stem cell lines and Interferon Sciences Inc., a public shell that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!